TECHWIRE 30
(CIX: WRAL30)  1,216.16  down arrow-3.17  (-0.26 %)  Updated: 08:10 PM EDT, May 22 2015
(NQ: Apple)  132.54  up arrow+1.15  (0.88 %)  Updated: 08:10 PM EDT, May 22 2015
(NY: QUINTILES)  69.70  up arrow+0.99  (1.44 %)  Updated: 06:40 PM EDT, May 22 2015
(OP: BASF SE)  96.80  down arrow-1.24  (-1.26 %)  Updated: 05:20 PM EDT, May 22 2015
(NQ: BioCryst)  11.42  up arrow+0.12  (1.06 %)  Updated: 08:10 PM EDT, May 22 2015
(NQ: BioDelivery)  8.10  down arrow-0.39  (-4.59 %)  Updated: 08:10 PM EDT, May 22 2015
(NQ: CEMP)  35.98  down arrow-0.67  (-1.83 %)  Updated: 08:10 PM EDT, May 22 2015
(NQ: Cisco Systems)  29.26  down arrow-0.17  (-0.58 %)  Updated: 08:10 PM EDT, May 22 2015
(NQ: Cree)  30.47  down arrow-0.09  (-0.29 %)  Updated: 08:10 PM EDT, May 22 2015
(NQ: DARA)  0.72    (-0.06 %)  Updated: 08:10 PM EDT, May 22 2015
(NY: EMC CORPORATION)  26.84  up arrow+0.05  (0.19 %)  Updated: 06:40 PM EDT, May 22 2015
(NQ: Extreme Networks)  2.62  up arrow+0.02  (0.77 %)  Updated: 08:10 PM EDT, May 22 2015
(NQ: FB)  80.54  up arrow+0.06  (0.07 %)  Updated: 08:10 PM EDT, May 22 2015
(NY: GLAXOSMITHKLINE)  45.26  down arrow-0.3  (-0.66 %)  Updated: 06:40 PM EDT, May 22 2015
(NQ: GOOG)  540.11  down arrow-2.4  (-0.44 %)  Updated: 08:10 PM EDT, May 22 2015
(NY: IBM)  172.22  down arrow-1.12  (-0.65 %)  Updated: 06:40 PM EDT, May 22 2015
(NY: LH)  121.42  up arrow+1.06  (0.88 %)  Updated: 06:40 PM EDT, May 22 2015
(OP: Lenovo Group)  33.43  down arrow-1.37  (-3.94 %)  Updated: 05:20 PM EDT, May 22 2015
(NY: MRK)  59.38  down arrow-0.72  (-1.2 %)  Updated: 06:40 PM EDT, May 22 2015
(NQ: Microsoft Corp)  46.90  down arrow-0.52  (-1.1 %)  Updated: 08:10 PM EDT, May 22 2015
(NQ: NTAP)  33.14  up arrow+1.37  (4.31 %)  Updated: 08:10 PM EDT, May 22 2015
(NY: NOVARTIS AG)  103.85  down arrow-0.94  (-0.9 %)  Updated: 06:40 PM EDT, May 22 2015
(OP: Novozymes A/S)  46.74  down arrow-0.66  (-1.39 %)  Updated: 05:20 PM EDT, May 22 2015
(NY: PFIZER)  34.28  down arrow-0.08  (-0.23 %)  Updated: 06:40 PM EDT, May 22 2015
(NQ: Pozen)  6.71  up arrow+0.04  (0.6 %)  Updated: 08:10 PM EDT, May 22 2015
(NY: RED HAT)  78.81  down arrow-0.02  (-0.03 %)  Updated: 06:40 PM EDT, May 22 2015
(NQ: BBRY)  10.48  up arrow+0.21  (2.04 %)  Updated: 08:10 PM EDT, May 22 2015
(NQ: Salix)  172.81    (0 %)  Updated: 08:10 PM EDT, Apr 01 2015
(NQ: SQI)  15.40  down arrow-0.17  (-1.09 %)  Updated: 08:10 PM EDT, May 22 2015

Posts tagged “Video game industry”

Updated July 17, 2009

Premium Lock FDA approves Raleigh-based BioDelivery Science’s powerful painkiller

BDSI Approval triggers $12 million payment to BDSI. Product, called Onsolis, targets breakthrough cancer pain and is delivered through dissolvable patch.

Updated October 13, 2008

Premium Lock BioDelivery Sciences promotes exec to chief technology spot

Niraj Vasisht is the new chief technical officer at BioDelivery Sciences International .

April 2, 2008

Premium Lock BioDelivery Sciences Receives $2.5 Million at Milestone

Meda AB Files for European Approval of BEMA™ Fentanyl

Updated January 15, 2008

Premium Lock BioDelivery Sciences to Expand Research for Breakthrough Pain Drug

BDSI Combination of narcotic, oral lozenge could be used to treat pain caused by other ailments beyond cancer.

Updated November 2, 2007

Premium Lock BioDelivery Sciences Moves HQ to Raleigh

BDSI Move to larger space made to accommodate more employees, company says.

Updated November 1, 2007

Premium Lock BioDelivery Sciences Files Application for Acute Pain Treatment

BDSI Morrisville-based company seeks FDA approval for ‘breakthrough cancer pain.’ BDSI hopes to launch sales in 2008.

September 10, 2007

Premium Lock BioDelivery Sciences to Pay $7M for Ownership of Drug Delivery technology

BDSI RTP-based firm buys all U.S. rights to oral delivery method from QLT USA.

Updated September 5, 2007

Premium Lock What a Relief: BDSI Lands $60M Deal for Rights to Cancer Pain Reliever

 Europe-based Meda pays Morrisville drug development firm $30M up front for North America rights. Meda had already secured European rights.

Updated July 3, 2007

Premium Lock Application Process for Cancer Drug on Target

BioDelivery Sciences International announced Monday that its June 28 pre-NDA meeting with the U.S. Food and Drug Administration regarding the company’s Phase III BEMA Fentanyl product went according to plan.

April 26, 2007

Premium Lock BioDelivery Sciences Stock Soars 30% on Positive Drug Trial News

BDSI Triangle-based drug development firm reports effectiveness in use of breakthrough pain killer.

Updated April 10, 2007

Premium Lock Drug Firm BDSI Names Marketing Executive

BDSI Al Medwar, who once worked for Triangle Pharmaceuticals, joins BDSI from EMD Pharmaceuticals.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith